Biora Therapeutics, Inc. (BIOR)
- Previous Close
3.4300 - Open
3.4400 - Bid 3.2100 x 100
- Ask 3.4400 x 100
- Day's Range
3.3100 - 3.4786 - 52 Week Range
3.3100 - 19.9000 - Volume
27,436 - Avg. Volume
38,924 - Market Cap (intraday)
12.318M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-49.3000 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
97.50
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
www.bioratherapeutics.comRecent News: BIOR
View MorePerformance Overview: BIOR
Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOR
View MoreValuation Measures
Market Cap
12.32M
Enterprise Value
53.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.35
Price/Book (mrq)
--
Enterprise Value/Revenue
62.74
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-125.06%
Return on Equity (ttm)
--
Revenue (ttm)
860k
Net Income Avi to Common (ttm)
-86.81M
Diluted EPS (ttm)
-49.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.33M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-19.18M
Research Analysis: BIOR
View MoreCompany Insights: BIOR
BIOR does not have Company Insights